Update shared on30 Jul 2025
Fair value Increased 71%Niagen Bioscience's consensus price target was significantly raised from $8.72 to $14.90, reflecting strong analyst confidence driven by successful clinical trial results, robust TruNiagen sales growth, and encouraging pipeline progress.
Analyst Commentary
- Positive clinical trial results published in a peer-reviewed journal demonstrated the safety and significant NAD+ level increase (~140%) from supplementation in patients with Werner syndrome, along with improvements in key clinical markers such as liver, kidney, and arterial health.
- Ongoing and upcoming clinical trials and studies present notable upside potential by potentially expanding Niagen Bioscience's addressable markets.
- Bullish analysts cite sustained strong sales growth of TruNiagen, the company’s core product, as a key driver for higher target prices.
- Immunity from the impact of tariffs protects Niagen Bioscience’s margins and competitiveness compared to peers vulnerable to trade policy fluctuations.
- Encouraging progress in pipeline initiatives, including the rollout of Niagen Plus in clinics, supports confidence in future growth and further validates bullish outlooks.
What's in the News
- Tru Niagen is now offered as an in-room amenity in all Equinox Hotel New York suites, and Niagen IV is available at the hotel's spa through NutriDrip.
- Secured exclusive global rights from Haukeland University Hospital to develop and commercialize nicotinamide riboside (NR) as a pharmaceutical for Parkinson's Disease, with access to robust clinical trial data (including the phase III NOPARK study).
- Published positive clinical results showing Niagen's safety and efficacy in individuals with Werner syndrome, demonstrating significant increases in NAD+ levels and improvement in cardiovascular and skin markers.
- Raised 2025 net sales growth guidance to 20–25% (from approximately 18%) and maintained profitability outlook despite higher administrative expenses, primarily from increased share-based compensation.
- Expanded network to nearly 600 clinics nationwide now offering Niagen IV and injections as pharmaceutical-grade NAD-boosting therapies.
Valuation Changes
Summary of Valuation Changes for Niagen Bioscience
- The Consensus Analyst Price Target has significantly risen from $8.72 to $14.90.
- The Future P/E for Niagen Bioscience has significantly risen from 41.28x to 59.36x.
- The Net Profit Margin for Niagen Bioscience has significantly risen from 13.21% to 14.70%.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.